Remibrutinib is an Orally Active BTK Inhibitor for Chronic Urticaria Research
Remibrutinib is a potent and orally active BTK inhibitor for Chronic urticaria (CU) research.
TAK-603 is a Potent and Orally Active Antirheumatic Agent for Adjuvant Arthritis Research
Anti-arthritis drugs are used to relieve or prevent arthritis symptoms (such as joint pain and Joint stiffness). Specifically, the impact of rheumatism on fertility and reproduction may be significant. Individuals…
SX 011 is an Orally Active p38 Inhibitor for Inflammation Research
The p38 MAPK pathway is a key regulatory factor for the biosynthesis of pro-inflammatory cytokines at the transcription and translation levels. There are four splicing variants in the p38 family:…
Seselin is an Orally Active Antifungal Agent for Inflammation Research
Antifungal agents are drugs that selectively eliminate fungal pathogens from the host with minimal toxicity. Meanwhile, bacteria are prokaryotes and therefore provide many structural and metabolic targets that differ from…
Relutrigine (PRAX-562) is an Orally Active Persistent Sodium Channel Inhibitor
The sodium channel is a complete membrane protein that forms the ion channel and transmits sodium ions (Na+) through the cell membrane. Besides, the sodium channel includes four similar domains.…
JBSNF-000028 is an Orally Active NNMT Inhibitor, with Anti-obesity Activity
Nicotinamide N-methyltransferase (NNMT) is a metabolic enzyme. Specifically, NNMT is involved in controlling methylation potential and influencing epigenetic modification of DNA and histones. Specifically, it uses the universal methyl donor…